Biotech | October 15, 2021
Exelixis in-licenses second anti-cancer compound from Aurigene
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The transaction is anticipated to close in the first quarter of 2022
The two plots are located in the heart of Gurugram close to Sectors 53 on the Golf Course Road and Sector 56 just minutes away from the other location
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
It tests for the presence or absence of ribonucleic acid (RNA) of Dengue (Type 1, 2 4) in serum or plasma from patients suspected of dengue viral infection.
Subscribe To Our Newsletter & Stay Updated
